Huaigeng Xu • UCSF Profiles

Huaigeng Xu, MD, PhD

Title(s)	Postdoctoral Scholar, Urology
School	School of Medicine
Address	35 Medical Center Way, #912A San Francisco CA 94143
Phone	415-476-2838
ORCID	0000-0002-4415-1287
vCard	Download vCard

Biography

Education and Training

CiRA, Kyoto University, Kyoto, Japan	PhD	03/2019	Medicine
Tsuruga Municipal Hospital, Tsuruga, Fukui, Japan		03/2015	Residency
Osaka Medical College, Takatsuki, Osaka, Japan	MD	03/2013	Medicine

Awards and Honors

Inoue Foundation for Science	2020	Inoue Research Award for Young Scientists
CiRA 2019 International Symposium	2019	Best Poster Presentation Award
CiRA, Kyoto University	2019	CiRA Encouragement Award
2018 CiRA Retreat	2018	2nd Best Oral Presentation Award
2017 CiRA Retreat	2017	Best Poster Presentation Award

Overview

Huaigeng Xu was born in China and grew up in Japan.
He obtained his MD and PhD in Japan and recently started working at UCSF from March 2020.

During his PhD, he generated low immunogenicity iPS cells by disrupting HLA genes via CRISPR-Cas9 based genome-editing (Xu et al, Cell Stem Cell, 2019).
During this work, he learned iPS cell culture and differentiation to blood cells, CRISPR-Cas9 genome editing, immunology (e.g. T cells, NK cells and immune rejection) and basic mouse experiments.

His personal interest is aging, and his ultimate goal in the future is to solve age-related health problems and manage his longevity.
He speaks both Japanese and Chinese, and he is willing to interact with a lot of people.

Interests

Aging, Immunology, Genome editing, Exosomal PD-L1, APCs, Senescence, HLA, Transplant Rejection

Featured Content

Featured Presentations

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng. 2023 Jan; 7(1):24-37. Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, Sakamoto S, Watanabe A, Ohara K, Wang B, Xu H, Minagawa A, Hotta A, Woltjen K, Uemura Y, Kodama Y, Seno H, Nakatsura T, Tamada K, Kaneko S. PMID: 36509913; PMCID: PMC9870784.

View in: PubMed Mentions: 22 Fields:
Bio Biomedical Engineering
Translation:Humans Animals Cells
Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Mol Ther Methods Clin Dev. 2022 Sep 08; 26:15-25. Kitano Y, Nishimura S, Kato TM, Ueda A, Takigawa K, Umekage M, Nomura M, Kawakami A, Ogawa H, Xu H, Hotta A, Takasu N, Tsukahara M. PMID: 35755947; PMCID: PMC9198376.

View in: PubMed Mentions: 12
Optimized electroporation of CRISPR-Cas9/gRNA ribonucleoprotein complex for selection-free homologous recombination in human pluripotent stem cells. STAR Protoc. 2021 Dec 17; 2(4):100965. Xu H, Kita Y, Bang U, Gee P, Hotta A. PMID: 34825222; PMCID: PMC8605105.

View in: PubMed Mentions: 7 Fields:
Bio Biology Sci Science
Translation:Humans Cells
Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells. Nat Biomed Eng. 2021 05; 5(5):429-440. Wang B, Iriguchi S, Waseda M, Ueda N, Ueda T, Xu H, Minagawa A, Ishikawa A, Yano H, Ishi T, Ito R, Goto M, Takahashi R, Uemura Y, Hotta A, Kaneko S. PMID: 34002062.

View in: PubMed Mentions: 61 Fields:
Bio Biomedical Engineering
Translation:Humans Animals Cells
Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein. Stem Cell Reports. 2021 Apr 13; 16(4):985-996. Kagita A, Lung MSY, Xu H, Kita Y, Sasakawa N, Iguchi T, Ono M, Wang XH, Gee P, Hotta A. PMID: 33711268; PMCID: PMC8072016.

View in: PubMed Mentions: 19 Fields:
Cel Cell Biology
Translation:Humans Cells
Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun. 2020 Mar 13; 11(1):1334. Gee P, Lung MSY, Okuzaki Y, Sasakawa N, Iguchi T, Makita Y, Hozumi H, Miura Y, Yang LF, Iwasaki M, Wang XH, Waller MA, Shirai N, Abe YO, Fujita Y, Watanabe K, Kagita A, Iwabuchi KA, Yasuda M, Xu H, Noda T, Komano J, Sakurai H, Inukai N, Hotta A. PMID: 32170079; PMCID: PMC7070030.

View in: PubMed Mentions: 124 Fields:
Bio Biology Sci Science
Translation:Humans Cells
iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020 01 14; 14(1):49-59. Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, Akasaka M, Nakamura S, Higashi N, Xu H, Matsumoto T, Fujio K, Manz MG, Hotta A, Takizawa H, Eto K, Sugimoto N. PMID: 31883921; PMCID: PMC6962657.

View in: PubMed Mentions: 31 Fields:
Cel Cell Biology
Translation:Humans Animals Cells
CRISPR-Cas3 induces broad and unidirectional genome editing in human cells. Nat Commun. 2019 12 06; 10(1):5302. Morisaka H, Yoshimi K, Okuzaki Y, Gee P, Kunihiro Y, Sonpho E, Xu H, Sasakawa N, Naito Y, Nakada S, Yamamoto T, Sano S, Hotta A, Takeda J, Mashimo T. PMID: 31811138; PMCID: PMC6897959.

View in: PubMed Mentions: 68 Fields:
Bio Biology Sci Science
Translation:Humans Cells
Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019 04 04; 24(4):566-578.e7. Xu H, Wang B, Ono M, Kagita A, Fujii K, Sasakawa N, Ueda T, Gee P, Nishikawa M, Nomura M, Kitaoka F, Takahashi T, Okita K, Yoshida Y, Kaneko S, Hotta A. PMID: 30853558.

View in: PubMed Mentions: 237 Fields:
Cel Cell Biology
Translation:Humans Animals Cells
Efficient mRNA delivery system utilizing chimeric VSVG-L7Ae virus-like particles. Biochem Biophys Res Commun. 2018 11 10; 505(4):1097-1102. Zhitnyuk Y, Gee P, Lung MSY, Sasakawa N, Xu H, Saito H, Hotta A. PMID: 30316514.

View in: PubMed Mentions: 8 Fields:
Bio Biochemistry Bio Biophysics
Translation:Humans Cells
Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells. Sci Rep. 2018 Jan 10; 8(1):310. Ishida K, Xu H, Sasakawa N, Lung MSY, Kudryashev JA, Gee P, Hotta A. PMID: 29321585; PMCID: PMC5762678.

View in: PubMed Mentions: 12 Fields:
Sci Science
Translation:Humans Cells
Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy. Stem Cells Int. 2017; 2017:8765154. Gee P, Xu H, Hotta A. PMID: 28607562; PMCID: PMC5451761.

View in: PubMed Mentions: 23